Two Directors at Mallinckrodt Plc bought 35,000 shares at between 8.466USD and 8.483USD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
The independent financial analyst theScreener just lowered the general evaluation of MALLINCKRODT (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date August 25, 2020, the closing price was USD 1.49 and its target price was...
New York, New York--(Newsfile Corp. - September 24, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" or the "Company") of the September 24, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Mallinckrodt stock or options between February 28, 2018 and July 16, 2019 and would like to discuss your legal rights, click here: . There is no cost or obligation to you.You can also contact us by calling Richard Gonnello to...
MNK currently trades near historical lows relative to UAFRS-based (Uniform) Earnings, with a 6.5x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to decline from a record high of 44% in 2017 to 10% through 2022, accompanied by 6% Uniform Asset growth going forward. Meanwhile, analysts have less bearish expectations, projecting Uniform ROA to decline to 36% through 2019, accompanied by 1% Uniform Asset growth. However, management is confident about their Achtar...
Mallinckrodt Public Limited Company (MNK:USA) currently trades near historical lows relative to UAFRS-based (Uniform) Earnings, with a 6.5x Uniform P/E, implying bearish expectations for the firm. However, management is confident in Acthar sales growth, the potential of ongoing studies, and their ability to sustain free cash flow. Specifically, management is confident in the growth trajectory and stability of Acthar sales, and in the potential of rheumatoid arthritis and multiple sclerosis stud...
Despite recognizing a $3.9 billion non-cash impairment in the quarter, Mallinckrodt’s fourth-quarter results and 2019 guidance--which includes 1% to 4% revenue growth and an adjusted EPS of $8.10 to $8.40--exceeded our expectations. Regardless, we don’t plan a major change to our fair value estimate and no-moat rating as we still have reservations about the long-term competitive outlook and key patent expirations, such as for Ofirmev. While we do expect portions of Mallinckrodt’s portfol...
Despite recognizing a $3.9 billion non-cash impairment in the quarter, Mallinckrodt’s fourth-quarter results and 2019 guidance--which includes 1% to 4% revenue growth and an adjusted EPS of $8.10 to $8.40--exceeded our expectations. Regardless, we don’t plan a major change to our fair value estimate and no-moat rating as we still have reservations about the long-term competitive outlook and key patent expirations, such as for Ofirmev. While we do expect portions of Mallinckrodt’s portfol...
We may boost our fair value estimate for no-moat Mallinckrodt as we review our assumptions. Despite a nearly 70-basis-point decline in adjusted gross margin from last year from product mix, the company’s selling and administrative expenses continue to come in better than our forecast, and management raised its year-end adjusted EPS outlook to $7.10 at the midpoint. Meanwhile, the company’s top line continues to mostly meet our expectations. Acthar Gel sales were down 6% from last year, and w...
Summary Marketline's Endo International plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Endo International plc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the...
We may boost our fair value estimate for no-moat Mallinckrodt as we review our assumptions. Despite a nearly 70-basis-point decline in adjusted gross margin from last year from product mix, the company’s selling and administrative expenses continue to come in better than our forecast, and management raised its year-end adjusted EPS outlook to $7.10 at the midpoint. Meanwhile, the company’s top line continues to mostly meet our expectations. Acthar Gel sales were down 6% from last year, and w...
We may boost our fair value estimate for no-moat Mallinckrodt as we review our assumptions. Despite a nearly 70-basis-point decline in adjusted gross margin from last year from product mix, the company’s selling and administrative expenses continue to come in better than our forecast, and management raised its year-end adjusted EPS outlook to $7.10 at the midpoint. Meanwhile, the company’s top line continues to mostly meet our expectations. Acthar Gel sales were down 6% from last year, and w...
To offset poor growth prospects in its legacy generics and medical imaging segments, Mallinckrodt has used acquisitions to enter the branded pharmaceutical market. We are skeptical of the potential results of this strategy, given Mallinckrodt's lack of existing branded pharmaceutical infrastructure to build on, little strategic overlap among acquired assets, and the seemingly high prices that the firm has paid for its targets. We prefer acquisitions that combine complementary assets that create ...
Mallinckrodt reported second-quarter results and raised year-end top- and bottom-line guidance above our expectations thanks to better-than-expected Achter sales and nearly 300 basis points of adjusted operating margin improvement from last year. A beneficial product mix and management’s efficiency efforts and integration of Sucampo drove the margin improvement above our expectations partially offset by a material increase in R&D expense. While we appreciate management’s focus to build the p...
Mallinckrodt reported second-quarter results and raised year-end top- and bottom-line guidance above our expectations thanks to better-than-expected Achter sales and nearly 300 basis points of adjusted operating margin improvement from last year. A beneficial product mix and management’s efficiency efforts and integration of Sucampo drove the margin improvement above our expectations partially offset by a material increase in R&D expense. While we appreciate management’s focus to build the p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.